Trevi Therapeutics, Inc. TRVI Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $33.48M-15.0% | $39.38M+66.3% | $23.68M+19.4% | $19.83M-13.7% | ||
| $15.85M+30.5% | $12.15M+18.6% | $10.24M+1.7% | $10.07M+6.1% | ||
| $49.33M-4.3% | $51.53M+51.9% | $33.92M+13.4% | $29.91M-7.9% | ||
| -$49.33M+4.3% | -$51.53M-51.9% | -$33.92M-13.4% | -$29.91M+7.9% | ||
| $6.51M+81.6% | $3.58M-25.8% | $4.83M+571% | $719K+148% | ||
| -$42.82M+10.7% | -$47.94M-64.8% | -$29.1M+0.3% | -$29.19M+14.1% | ||
| -$63K— | —— | —— | -$36K-71.4% | ||
| -$42.76M+10.8% | -$47.91M-64.8% | -$29.07M+0.3% | -$29.15M+14.1% | ||
| -$0.32+31.9% | -$0.47-62.1% | -$0.29+43.1% | -$0.51+66.0% | ||
| -$49.18M+4.3% | -$51.38M-52.0% | -$33.8M-13.2% | -$29.86M+7.9% | ||
| -$49.33M+4.3% | -$51.53M-51.9% | -$33.92M-13.4% | -$29.91M+7.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Trevi Therapeutics, Inc. profitable?
- Trevi Therapeutics, Inc. is not currently profitable: it reported a net loss of $45.6M over the trailing twelve months.
- What is Trevi Therapeutics, Inc.'s earnings per share?
- Trevi Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.32.
- Where does Trevi Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Trevi Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.